Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27413544 | 0.92 | GRIK1 (0.49) | SLC1A2SLC1A1GRIK1GRIK2TP53 | |
| SCHEMBL27703023 | 0.86 | — | — | |
| SCHEMBL3079688 | 0.85 | SLC1A2 (0.44) | CA2CA1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL9282670 | 0.84 | SLC1A2 (0.47) | CA2CA1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL221495 | 0.83 | SLC1A2 (0.46) | CA2CA1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL15212136 | 0.81 | CHRM2 (0.37) | CA2CA1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL27922571 | 0.81 | SLC1A2 (0.44) | CA2CA1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL26666190 | 0.80 | GSR (0.40) | DPP7DPP8DPP4DPP9CHRM2 | |
| SCHEMBL27926569 | 0.80 | LMNA (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11598110 | 0.79 | GRIK1 (0.46) | CA1SLC1A2SLC1A1SLC1A3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209448-A | Cationic steroidal antimicrobial compounds and methods of making such compounds | 布莱阿姆青年大学 | 2023-06-02 | — | — | CN | claimed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-116209669-A | Cationic steroidal antimicrobial compounds with endogenous groups | 布莱阿姆青年大学 | 2023-06-02 | — | — | CN | disclosed |
| CN-116209448-A | Cationic steroidal antimicrobial compounds and methods of making such compounds | 布莱阿姆青年大学 | 2023-06-02 | — | — | CN | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CA2 2242/4885CA1 1024/4885SLC1A2 4271/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CA2 2242/4885CA1 1024/4885SLC1A2 4271/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CA2 2242/4885CA1 1024/4885SLC1A2 4271/4885 |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CA2 2242/4885CA1 1024/4885SLC1A2 4271/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CA2 2242/4885CA1 1024/4885SLC1A2 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.